• Adjunctive rTMS and AEDs do not differ significantly in seizure frequency reduction
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Introduction
Seizure control is not achieved with a single anti-epileptic drug (AES) in up to one-third of those with focal-onset seizures (1) . Dose escalation and addition of a new AED are strategies to control seizure frequency, but are met frequently with side effects (2) . Treatment associated adverse events span a spectrum of severity, each with varying decrements to quality of life (3).
Thus, novel treatments with differing side effect profiles should be evaluated in the context of utility (efficacy corrected by adverse treatment effects).
When novel epilepsy therapies arise, such as repetitive transcranial magnetic stimulation (rTMS), proof of concept and safety studies often lack direct quality of life end points. Utility analyses can extrapolate quality of life impact by assessing more "traditional" outcome metrics of efficacy and side effects (4) (5) (6) . Here, we sought to use existing seizure frequency reduction and side effect incidence data to predict potential improvements in quality of life imparted by rTMS for adults with focal epilepsy compared to the addition of a new AED. A utility model was employed to compare early results from rTMS studies to contemporary AED clinical trial data.
Methods
A structured literature search captured clinical studies of AEDs and TMS in adults with refractory focal epilepsy (see Supplementary Materials). Pooled mean values from AEDs, rTMS and placebo treatment of each of clinical outcome variable collected were obtained using random-effects, inverse-variance weighted meta-analysis of observational data standards (7) . We created a decision analytical model to estimate the expected health-related quality of life (HrQOL) changes of AED and rTMS treatment groups compared to placebo control (Supp. Figure 1 ). HrQOL was expressed in utility units, which are based on relative patient preferences for health states, ranging from 0 (death) to 1 (perfect health). Our utility calculation considered the quality of life both added by a treatment's efficacy (seizure frequency reduction) and lost because of adverse events. Seizure frequency reduction and adverse effects (safety) were mapped to HrQOL utilizing published parameters (6, 8) . The primary analysis compared expected utilities, by populating a decision tree (Supp. Figure 1) 
Safety: Side effects and Complications with Treatment
The pairwise differences in the mean number of adverse events per patient between the three cohorts were each significant (p<0.001), with rTMS (incidence 12.4 ± 2.4%) performing better than placebo (incidence 107.6 ± 10.5%), which performed better than AEDs (incidence 206.5 ± 67.5%, i.e. the average AED patient experiences just over 2 events during a trial).
Adverse events are summarized in Supp. Table 2 . When calculating utility, the AED effect was defined as the difference between the AED and placebo incidences (98.9 ± 22.3%), and the placebo event rate was assigned to 0. For each adverse event the associated utility and reference are listed in Supp. Table 3 .
Utility
Pooled seizure frequency reductions and adverse event rates were utilized as model parameters. Table 1 highlights the significant differences in overall utility values among all 3 treatment groups (p < 0.001 for all three pairwise comparisons). From these data, we predict rTMS to have a superior treatment utility than an additional AEDs, which is superior to placebo.
Discussion
Our model predicts rTMS is more effective at maximizing HrQOL than an additional AED, despite no significant difference in reducing seizure frequency. rTMS is associated with significantly fewer adverse effects than AEDs, thus providing a significantly higher quality of life improvement as predicted by our regression model (p < 0.001).
Patient differences, including type of epilepsy, number of AEDs prescribed, psychological conditions, as well as demographic differences including baseline severity, may influence rTMS outcomes. Seynaeve et al. speculate that use of multiple AEDs could limit the ability of rTMS to induce synaptic changes (10) . Thus, rTMS may be most effective when used early after the diagnosis of epilepsy or as an adjunctive to AEDs.
Adverse Effects
When a placebo group was present in the rTMS trials evaluated, there was no difference in adverse effects between sham and active group stimulation groups (9, 10), suggesting adverse effects may be mitigated by adjusting the treatment environment (10) . The large majority of adverse effects in the rTMS articles were reported as mild. In contrast, adverse effects from AEDs were the primary reason for patient medication discontinuation.
Limitations
A standard rTMS protocol has not been developed for epilepsy, thus variation in treatment outcomes may arise from inconsistencies in protocols. Standardization of TMS treatment length and clinical follow up assessments may help resolve time-dependent treatment effects. As with all models, several included assumptions may impact our predictions. For example, mapping of reduction of seizure frequency and treatment complications onto a utility scale is indirect and may obscure outcome estimation. However, this approach is ideal to describe quality of life effects, which are an inherent integration of treatment efficacy and side effects.
Conclusions
Our model predicts that adjunctive rTMS imparts superior improvement in quality of life compared to an additional AED primarily due to fewer side effects. Critically, the data provided here are insufficient to warrant discontinuation of a tolerated and effective AED for a trial of rTMS. However, we support continued investigation of rTMS for focal-onset epilepsy as a sideeffect sparing therapy with comparable seizure reduction efficacy to a new AED. Compiled clinical parameters of efficacy and safety, were processed via our decision tree model (pictured in Supp. Figure 1) to generate utility values. rTMS resulted in the highest overall utility. ANOVA of these results reveals highly significant differences in both global and pairwise outcomes (F = 1936, p < 0.001). Percentages represent mean improvement from post-treatment compared to baseline. 
Comparison of Utilities

